Surgery remains a viable option for faster relief in hidradenitis suppurativa, expert says
Dermatology expert Dr. Amit Garg argues that surgery should no longer be viewed as a last resort for hidradenitis suppurativa (HS), despite the recent wave of effective systemic anti-inflammatory therapies. While new targeted treatments have expanded options for controlling HS activity, surgery can offer faster resolution of highly symptomatic lesions. The traditional view of surgery as a treatment of last resort has shifted, with ambulatory surgery now considered a viable option for faster clinical benefit in appropriate cases.
Key quotes
Surgery has traditionally been considered a treatment of last resort, but I think this has completely changed.
In the past few years, the list of highly targeted systemic anti-inflammatory treatments effective for hidradenitis suppurativa (HS) activity has grown substantially, but surgery should still be considered an option to accelerate resolution of highly symptomatic lesions.
From the article
A wave of recently approved therapies has improved options for the control of hidradenitis suppurativa, but surgery remains a possible option for faster clinical benefit.
Continue reading on mdsc.peYou might also wanna read
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
clinicaltrials.gov·1d ago
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
clinicaltrials.gov·1d ago

Spatial Analysis Reveals Socioenvironmental Drivers of Hidradenitis Suppurativa in Boston Area
This cross-sectional study uses spatial epidemiological methods to analyze how environmental and social factors influence the distribution o
No grafts, no scars: Inside the Hamilton medical breakthrough that saved an 18-year-old’s face
A Synergistic Approach to Remodeling of Photodamaegd Skin: Exploring Laser-Assisted Biostimulator Delivery
clinicaltrials.gov·7d ago

Endolaser avança na cirurgia plástica reparadora
Extra Online·1d ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.